MA33880B1 - Nouveaux composés efficaces comme inhibiteurs de la xanthine oxydase, leur procédé de préparation et composition pharmaceutique les contenant - Google Patents

Nouveaux composés efficaces comme inhibiteurs de la xanthine oxydase, leur procédé de préparation et composition pharmaceutique les contenant

Info

Publication number
MA33880B1
MA33880B1 MA34731A MA34731A MA33880B1 MA 33880 B1 MA33880 B1 MA 33880B1 MA 34731 A MA34731 A MA 34731A MA 34731 A MA34731 A MA 34731A MA 33880 B1 MA33880 B1 MA 33880B1
Authority
MA
Morocco
Prior art keywords
preparation
pharmaceutical composition
novel compounds
xanthine oxidase
composition containing
Prior art date
Application number
MA34731A
Other languages
Arabic (ar)
English (en)
Inventor
Jeong Uk Song
Geun Tae Kim
Sung Pil Choi
Cheol Kyu Jung
Deok Seong Park
Eun Sil Choi
Tae Hun Kim
Hyun Jung Park
Wan Su Park
Heui Sul Park
Ki Chul Koo
Vasily Artemov
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43857261&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33880(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of MA33880B1 publication Critical patent/MA33880B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention porte sur de nouveaux composés qui sont efficaces comme inhibiteur de la xanthine oxydase, sur leur procédé de préparation et sur une composition pharmaceutique comprenant une quantité thérapeutiquement efficace de ceux-ci.
MA34731A 2009-10-07 2010-10-04 Nouveaux composés efficaces comme inhibiteurs de la xanthine oxydase, leur procédé de préparation et composition pharmaceutique les contenant MA33880B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20090095363 2009-10-07
PCT/KR2010/006760 WO2011043568A2 (fr) 2009-10-07 2010-10-04 Nouveaux composés efficaces comme inhibiteurs de la xanthine oxydase, leur procédé de préparation et composition pharmaceutique les contenant

Publications (1)

Publication Number Publication Date
MA33880B1 true MA33880B1 (fr) 2013-01-02

Family

ID=43857261

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34731A MA33880B1 (fr) 2009-10-07 2010-10-04 Nouveaux composés efficaces comme inhibiteurs de la xanthine oxydase, leur procédé de préparation et composition pharmaceutique les contenant

Country Status (26)

Country Link
US (1) US8729273B2 (fr)
EP (1) EP2467378B1 (fr)
JP (1) JP5702392B2 (fr)
KR (1) KR101751325B1 (fr)
CN (1) CN102574839B (fr)
AP (1) AP3346A (fr)
AR (1) AR078504A1 (fr)
AU (1) AU2010304091B2 (fr)
BR (1) BR112012007828B8 (fr)
CA (1) CA2774133C (fr)
CL (1) CL2012000738A1 (fr)
CO (1) CO6430501A2 (fr)
EA (1) EA021025B1 (fr)
EC (1) ECSP12011793A (fr)
ES (1) ES2599829T3 (fr)
IL (1) IL218669A (fr)
MA (1) MA33880B1 (fr)
MX (1) MX2012003782A (fr)
MY (1) MY162813A (fr)
PE (1) PE20121088A1 (fr)
SG (1) SG179186A1 (fr)
TR (1) TR201203989T1 (fr)
TW (1) TWI423962B (fr)
UA (1) UA110197C2 (fr)
WO (1) WO2011043568A2 (fr)
ZA (1) ZA201202544B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI548630B (zh) * 2011-04-06 2016-09-11 Ｌｇ生命科學有限公司 １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶型及其製造方法
SI2750677T1 (sl) * 2011-08-30 2017-10-30 Chdi Foundation, Inc. Inhibitorji kinurenin-3-monooksigenaze, farmacevtski sestavki in postopki njihove uporabe
CN105189476B (zh) 2013-03-29 2017-07-07 帝人制药株式会社 吡唑衍生物
AU2015289492B2 (en) 2014-07-17 2020-02-20 Chdi Foundation, Inc. Methods and compositions for treating HIV-related disorders
CN104774172B (zh) * 2015-04-08 2017-03-22 河南师范大学 一种3‑氰基吲哚类化合物的合成方法
RU2733750C2 (ru) * 2015-09-02 2020-10-06 Саншайн Лейк Фарма Ко., Лтд. Производные карбоксизамещенных (гетеро)ароматических колец, способ их получения и применение
CN106008488B (zh) * 2016-05-20 2018-10-30 广东东阳光药业有限公司 氰基吲哚类衍生物及其制备方法和用途
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
CN110612286A (zh) * 2017-02-28 2019-12-24 广东东阳光药业有限公司 氰基取代的稠合双环衍生物及其制备方法和用途
PL3793588T3 (pl) 2018-05-18 2025-09-01 Bioverativ Therapeutics Inc. Sposoby leczenia hemofilii a
KR102308713B1 (ko) * 2018-06-01 2021-10-05 (주)오토파지사이언스 신규한 화합물 및 이를 포함하는 약학적 조성물
CN111072647B (zh) * 2019-12-11 2021-02-26 沈阳药科大学 3-取代吲哚-5-氧代-4,5-二氢-1,2,4-噁二唑类化合物及其用途
CN111072634B (zh) * 2020-01-03 2022-07-22 中国医科大学 1-取代-3-取代-5-取代酰胺-1h-吲哚类化合物及其制备方法和应用
US20240000750A1 (en) 2020-11-04 2024-01-04 Lg Chem, Ltd. Method for preparing crystalline particles of 1-(3-cyano-1-isopropyl-indole-5-yl)pyrazole-4-carboxylic acid, and pharmaceutical composition comprising same
PE20240222A1 (es) * 2020-12-01 2024-02-16 Lg Chemical Ltd Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico y un proceso para su preparacion
PE20230850A1 (es) 2020-12-01 2023-05-23 Lg Chemical Ltd Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico y un proceso para su preparacion
CN112920170B (zh) * 2021-01-29 2023-06-20 中国医科大学 N-（吲哚-5-基）芳香杂环酰胺类化合物及其制备方法和用途
TWI903066B (zh) * 2021-04-16 2025-11-01 南韓商Ｌｇ化學股份有限公司 包含１－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸之口服用複合調配物
WO2022231262A1 (fr) * 2021-04-27 2022-11-03 주식회사 엘지화학 Procédé de préparation d'un inhibiteur de xanthine oxydase
KR102708081B1 (ko) * 2021-04-27 2024-09-20 주식회사 엘지화학 잔틴 옥시다아제 저해제 합성을 위한 중간체의 제조 방법
US20240262809A1 (en) * 2021-04-27 2024-08-08 Lg Chem, Ltd. Method for preparing intermediate for synthesis of xanthine oxidase inhibitor
CN115160299B (zh) * 2021-04-29 2024-08-16 江苏新元素医药科技有限公司 一类黄嘌呤氧化酶抑制剂
PE20240242A1 (es) * 2021-06-15 2024-02-16 Lg Chemical Ltd Una composicion farmaceutica que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico
AR126164A1 (es) * 2021-06-17 2023-09-27 Lg Chemical Ltd Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico
TWI822151B (zh) 2021-07-02 2023-11-11 南韓商Ｌｇ化學股份有限公司 製備黃嘌呤氧化酶抑制劑的方法
AU2022302841A1 (en) 2021-07-02 2023-12-21 Lg Chem, Ltd. Method for preparing intermediate for synthesis of xanthine oxidase inhibitor
WO2023208103A1 (fr) 2022-04-27 2023-11-02 江苏新元素医药科技有限公司 Composé pouvant être utilisé pour la goutte
CN116715633B (zh) * 2022-04-27 2025-08-12 杭州新元素药业股份有限公司 可用于降尿酸的化合物
CN116283946B (zh) * 2023-03-27 2024-05-07 武汉工程大学 5-(n-取代吲哚-5-基)异噁唑-3-甲酸衍生物及其合成方法和应用
KR20250009377A (ko) 2023-07-10 2025-01-17 주식회사 엘지화학 잔틴 옥시다아제 저해제 합성을 위한 중간체의 제조 방법
CN118598859B (zh) * 2024-05-21 2025-08-19 武汉工程大学 一种含氮杂环吲哚类黄嘌呤氧化酶抑制剂及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2092580T3 (es) 1990-11-30 1996-12-01 Teijin Ltd Derivado de 2-ariltiazol y composicion farmaceutica que contiene el mismo.
ID21775A (id) 1996-10-25 1999-07-22 Yoshitomi Pharmaceutical Senyawa-senyawa 1-fenilpirazol dan penggunaan farmasinya
WO2002002551A1 (fr) * 2000-06-30 2002-01-10 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones et leur utilisation comme inhibiteurs des proteine kinases
DK1299382T3 (da) * 2000-07-10 2006-01-16 Bristol Myers Squibb Co Præparat og antiviral virkning af substituerede indoloxoeddikesyrepiperazinderivater
WO2008011131A2 (fr) * 2006-07-21 2008-01-24 Takeda Pharmaceutical Company Limited Composés amidés
DE10163991A1 (de) * 2001-12-24 2003-07-03 Merck Patent Gmbh Pyrrolo-pyrimidine
AU2003249535A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors
WO2007004688A1 (fr) * 2005-07-01 2007-01-11 Nippon Chemiphar Co., Ltd. Inhibiteur de xanthine oxydase
CN101282934A (zh) 2005-10-07 2008-10-08 安斯泰来制药株式会社 三芳基羧酸衍生物
US8188113B2 (en) * 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
JP2008179621A (ja) * 2006-12-28 2008-08-07 Taisho Pharmaceutical Co Ltd 含窒素飽和複素環化合物
WO2008126770A1 (fr) 2007-04-05 2008-10-23 Astellas Pharma Inc. Procédé de production d'un dérivé d'acide triarylcarboxylique
JP5330989B2 (ja) 2007-04-11 2013-10-30 キッセイ薬品工業株式会社 （アザ）インドール誘導体及びその医薬用途
MX2009010491A (es) 2007-04-11 2009-11-09 Kissei Pharmaceutical Derivado heterociclico de 5 miembros y su uso para propositos medicos.
CA2739058A1 (fr) * 2008-10-15 2010-04-22 Kissei Pharmaceutical Co., Ltd. Derive heterocyclique fusionne et son utilisation a des fins medicales
WO2010045186A2 (fr) 2008-10-16 2010-04-22 Automatic Bar Controls, Inc. Dispositif et procédé et plateau tournant pour distribuer un produit alimentaire sur demande
CA2738929A1 (fr) * 2008-10-17 2010-04-22 Boehringer Ingelheim International Gmbh Composes indole a substitution heteroaryle utilises comme inhibiteurs de mmp-13
BR112012006630A2 (pt) * 2009-09-24 2016-05-03 Hoffmann La Roche derivados em indol como moduladores dos canais de cálcio ativados para liberação de cálcio (crac)

Also Published As

Publication number Publication date
BR112012007828A2 (pt) 2016-03-08
EA021025B1 (ru) 2015-03-31
AU2010304091B2 (en) 2016-06-09
UA110197C2 (ru) 2015-12-10
TW201118077A (en) 2011-06-01
WO2011043568A2 (fr) 2011-04-14
CO6430501A2 (es) 2012-04-30
ZA201202544B (en) 2012-12-29
CL2012000738A1 (es) 2012-09-14
EP2467378B1 (fr) 2016-07-27
ES2599829T3 (es) 2017-02-03
EA201270520A1 (ru) 2012-10-30
EP2467378A4 (fr) 2013-04-24
CN102574839A (zh) 2012-07-11
MX2012003782A (es) 2012-08-31
TWI423962B (zh) 2014-01-21
WO2011043568A3 (fr) 2011-09-29
CN102574839B (zh) 2015-11-25
AP2012006191A0 (en) 2012-04-30
BR112012007828B8 (pt) 2021-05-25
MY162813A (en) 2017-07-31
US8729273B2 (en) 2014-05-20
JP5702392B2 (ja) 2015-04-15
TR201203989T1 (tr) 2012-09-21
JP2013507355A (ja) 2013-03-04
CA2774133C (fr) 2019-06-25
KR20110037883A (ko) 2011-04-13
AP3346A (en) 2015-07-31
KR101751325B1 (ko) 2017-06-27
HK1170224A1 (zh) 2013-02-22
EP2467378A2 (fr) 2012-06-27
IL218669A (en) 2016-08-31
PE20121088A1 (es) 2012-08-17
IL218669A0 (en) 2012-05-31
US20120184582A1 (en) 2012-07-19
ECSP12011793A (es) 2012-05-30
SG179186A1 (en) 2012-05-30
CA2774133A1 (fr) 2011-04-14
BR112012007828B1 (pt) 2021-01-12
AR078504A1 (es) 2011-11-09
AU2010304091A1 (en) 2012-04-19

Similar Documents

Publication Publication Date Title
MA33880B1 (fr) Nouveaux composés efficaces comme inhibiteurs de la xanthine oxydase, leur procédé de préparation et composition pharmaceutique les contenant
MA53219B1 (fr) Nouveaux composés hétérocycliques en tant qu'inhibiteurs de monoacylglycérol lipase
MA33745B1 (fr) Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes
MA35404B1 (fr) Composés pour le traitement de la toxicomanie
WO2010093191A3 (fr) Nouveaux composés efficaces en tant qu'inhibiteurs de xanthine oxydase, leur procédé de préparation et composition pharmaceutique les contenant
MA39193A1 (fr) Modulateurs du gpr6 à base de tétrahydropyridopyrazines
HRP20070043A2 (hr) Antivirusna sredstva
EA201200018A1 (ru) Триазольные соединения, несущие серосодержащий заместитель
CO6190517A2 (es) Derivados de 2-[1-fenil-5-hidroxi-4alfa-metil-hexahidrociclopenta [f]indazol-5-il]etil fenilo como ligandos del receptor glucocorticoide
EA201000024A1 (ru) Новые производные дикарбоновых кислот в качестве агонистов рецептора s1p1
TN2009000138A1 (fr) Biaryl-ether-urees
EA200971140A1 (ru) Триарильные соединения и композиции, их содержащие
HRP20070078A2 (hr) Fosfonatni analozi spojeva koji inhibiraju hiv
EA201070039A1 (ru) Спироциклы в качестве ингибиторов 11-бета гидроксилстероиддегидрогеназы типа 1
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
MA32391B1 (fr) Activateurs de la glucokinase
MA32471B1 (fr) Composés de borates esters et compositions pharmaceutiques contenant des composés
MY150596A (en) Hsp90 inhibitors
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
MA33492B1 (fr) Inhibiteurs de bace
MX2009011754A (es) Inhibidores de enzima de diacilglicerol o-aciltransferasa tipo 1.
MA34175B1 (fr) Anticorps anti-cxcr4 humanisés pour le traitement de cancer
MA35886B1 (fr) Dérivés de benzylsulfanilamide utilisés comme inhibiteurs -2 mogat
MA34301B1 (fr) Nouveaux procedes
DE602007005387D1 (de) Ptors